DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
ATECEGATRAN METOXIL
2
Small molecule
Investigational
Unknown
Unknown
Atrial Fibrillation
Unknown
ATECEGATRAN METOXIL
×
Maximum Phase:
2
First Approval:
None
UNII:
4GU1D587JV
Molecule Type:
Small molecule
Molecular Formula:
C22H23ClF2N4O5
Molecular Weight:
496.9
AlogP:
2.37
PSA:
123.98
HBD:
4.0
HBA:
#RotB:
9.0
Source:
CG-400549
2
Small molecule
Investigational
Unknown
Unknown
Eczema
Enoyl-[acyl-carrier-protein] reductase (FabI) inhibitor
CG-400549
×
Maximum Phase:
2
First Approval:
None
UNII:
4X6T64D64X
Molecule Type:
Small molecule
Molecular Formula:
C19H20N2O2S
Molecular Weight:
340.45
AlogP:
3.47
PSA:
57.25
HBD:
1.0
HBA:
#RotB:
6.0
Source:
MK-0249
2
Small molecule
Investigational
Unknown
Unknown
Dementia; Alzheimer Disease; Attention Deficit Disorder with Hyperactivity; Schizophrenia; Sleep Apnea, Obstructive
Histamine H3 receptor inverse agonist
MK-0249
×
Maximum Phase:
2
First Approval:
None
UNII:
KF50235Q04
Molecule Type:
Small molecule
Molecular Formula:
C23H24F3N3O2
Molecular Weight:
431.46
AlogP:
4.58
PSA:
47.36
HBD:
0.0
HBA:
#RotB:
6.0
Source:
PREDNIMUSTINE
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma; Neoplasms
Unknown
PREDNIMUSTINE
×
Maximum Phase:
2
First Approval:
None
UNII:
9403SIO2S8
Molecule Type:
Small molecule
Molecular Formula:
C35H45Cl2NO6
Molecular Weight:
646.65
AlogP:
5.42
PSA:
104.14
HBD:
2.0
HBA:
#RotB:
12.0
Source:
AMITIFADINE HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major
Unknown
AMITIFADINE HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
R01R720TVG
Molecule Type:
Small molecule
Molecular Formula:
C11H12Cl3N
Molecular Weight:
264.58
AlogP:
2.85
PSA:
12.03
HBD:
1.0
HBA:
#RotB:
1.0
Source:
SELURAMPANEL
2
Small molecule
Investigational
Unknown
Unknown
Epilepsy; Epilepsy, Reflex; Migraine Disorders; Multiple Sclerosis; Muscle Spasticity; Seizures; Tinnitus
Glutamate receptor ionotropic AMPA antagonist
SELURAMPANEL
×
Maximum Phase:
2
First Approval:
None
UNII:
7WG1MR7DAR
Molecule Type:
Small molecule
Molecular Formula:
C16H19N5O4S
Molecular Weight:
377.43
AlogP:
0.72
PSA:
118.85
HBD:
2.0
HBA:
#RotB:
4.0
Source:
BURIXAFOR
2
Small molecule
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant; Hodgkin Disease; Lymphoma, Non-Hodgkin; Multiple Myeloma
C-X-C chemokine receptor type 4 antagonist
BURIXAFOR
×
Maximum Phase:
2
First Approval:
None
UNII:
2G17Y0Q20G
Molecule Type:
Small molecule
Molecular Formula:
C27H51N8O3P
Molecular Weight:
566.73
AlogP:
2.48
PSA:
151.9
HBD:
6.0
HBA:
#RotB:
14.0
Source:
EDOTREOTIDE
2
Small molecule
Investigational
Unknown
Unknown
Neuroendocrine Tumors
Unknown
EDOTREOTIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
U194AS08HZ
Molecule Type:
Small molecule
Molecular Formula:
C65H92N14O18S2
Molecular Weight:
1421.66
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
UK-390,957
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
UK-390,957
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GSK-1004723
2
Small molecule
Investigational
Unknown
Unknown
Rhinitis, Allergic, Seasonal
Histamine H1 receptor antagonist
GSK-1004723
×
Maximum Phase:
2
First Approval:
None
UNII:
S08212J4ZR
Molecule Type:
Small molecule
Molecular Formula:
C39H49ClN4O2
Molecular Weight:
641.3
AlogP:
7.77
PSA:
50.6
HBD:
0.0
HBA:
#RotB:
14.0
Source:
LY2452473
2
Small molecule
Investigational
Unknown
Unknown
Erectile Dysfunction; Prostatic Hyperplasia; Prostatic Neoplasms, Castration-Resistant
Androgen Receptor modulator
LY2452473
×
Maximum Phase:
2
First Approval:
None
UNII:
XKW9MYF94Y
Molecule Type:
Small molecule
Molecular Formula:
C22H22N4O2
Molecular Weight:
374.44
AlogP:
3.56
PSA:
79.94
HBD:
1.0
HBA:
#RotB:
4.0
Source:
COBALAMIN
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Supplement
COBALAMIN
×
Maximum Phase:
2
First Approval:
None
UNII:
8406EY2OQA
Molecule Type:
Small molecule
Molecular Formula:
C62H88CoN13O14P
Molecular Weight:
1329.37
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
GSK232802
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GSK232802
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CHOLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CHOLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C25H42O5
Molecular Weight:
422.61
AlogP:
3.84
PSA:
97.99
HBD:
4.0
HBA:
#RotB:
4.0
Source:
ABACAVIR HYDROXYACETATE
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis
Unknown
ABACAVIR HYDROXYACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
B3C7MG354B
Molecule Type:
Small molecule
Molecular Formula:
C16H20N6O3
Molecular Weight:
344.38
AlogP:
0.64
PSA:
128.18
HBD:
3.0
HBA:
#RotB:
6.0
Source:
BILR 355
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
BILR 355
×
Maximum Phase:
2
First Approval:
None
UNII:
V7T28EEE1C
Molecule Type:
Small molecule
Molecular Formula:
C25H23N5O3
Molecular Weight:
441.49
AlogP:
3.63
PSA:
85.5
HBD:
0.0
HBA:
#RotB:
5.0
Source:
PLEVITREXED
2
Small molecule
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Unknown
PLEVITREXED
×
Maximum Phase:
2
First Approval:
None
UNII:
L9P2881C3H
Molecule Type:
Small molecule
Molecular Formula:
C26H25FN8O4
Molecular Weight:
532.54
AlogP:
2.06
PSA:
170.11
HBD:
4.0
HBA:
#RotB:
10.0
Source:
CC-401
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid
c-Jun N-terminal kinase 1 inhibitor
CC-401
×
Maximum Phase:
2
First Approval:
None
UNII:
NOE38VQA1W
Molecule Type:
Small molecule
Molecular Formula:
C22H24N6O
Molecular Weight:
388.48
AlogP:
3.88
PSA:
82.72
HBD:
2.0
HBA:
#RotB:
6.0
Source:
FORODESINE HCL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FORODESINE HCL
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MGCD265
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MGCD265
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CAYSTON
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CAYSTON
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CP-601927
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major
Neuronal acetylcholine receptor; alpha4/beta2 partial agonist
CP-601927
×
Maximum Phase:
2
First Approval:
None
UNII:
VI5LR1EU47
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CPI 613
2
Small molecule
Investigational
Unknown
Unknown
Biliary Tract Neoplasms; Sarcoma; Carcinoma, Pancreatic Ductal; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Neoplasms; Leukemia, Myeloid, Acute; Pancreatic Neoplasms
Unknown
CPI 613
×
Maximum Phase:
2
First Approval:
None
UNII:
E76113IR49
Molecule Type:
Small molecule
Molecular Formula:
C22H28O2S2
Molecular Weight:
388.6
AlogP:
6.26
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
13.0
Source:
CHLORSULFAQUINOXALINE
2
Small molecule
Investigational
Unknown
Unknown
Colorectal Neoplasms; Lung Neoplasms
Unknown
CHLORSULFAQUINOXALINE
×
Maximum Phase:
2
First Approval:
None
UNII:
O0408QB48D
Molecule Type:
Small molecule
Molecular Formula:
C14H11ClN4O2S
Molecular Weight:
334.79
AlogP:
2.67
PSA:
97.97
HBD:
2.0
HBA:
#RotB:
3.0
Source:
APITOLISIB
2
Small molecule
Investigational
Unknown
Unknown
Lymphoma, Non-Hodgkin; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Carcinoma, Renal Cell; Endometrial Neoplasms
PI3-kinase class I inhibitor
APITOLISIB
×
Maximum Phase:
2
First Approval:
None
UNII:
1C854K1MIJ
Molecule Type:
Small molecule
Molecular Formula:
C23H30N8O3S
Molecular Weight:
498.61
AlogP:
0.9
PSA:
133.83
HBD:
2.0
HBA:
#RotB:
5.0
Source:
RO-24-7429
2
Small molecule
Investigational
Unknown
Unknown
HIV Infections
Human immunodeficiency virus type 1 Tat protein antagonist
RO-24-7429
×
Maximum Phase:
2
First Approval:
None
UNII:
MLW2GKK8LI
Molecule Type:
Small molecule
Molecular Formula:
C14H13ClN4
Molecular Weight:
272.74
AlogP:
2.77
PSA:
52.54
HBD:
2.0
HBA:
#RotB:
1.0
Source:
PRADEFOVIR
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PRADEFOVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
GZE85Q9Q61
Molecule Type:
Small molecule
Molecular Formula:
C17H19ClN5O4P
Molecular Weight:
423.8
AlogP:
3.41
PSA:
114.38
HBD:
1.0
HBA:
#RotB:
6.0
Source:
TALMAPIMOD
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Multiple Myeloma
MAP kinase p38 alpha inhibitor
TALMAPIMOD
×
Maximum Phase:
2
First Approval:
None
UNII:
B1E00KQ6NT
Molecule Type:
Small molecule
Molecular Formula:
C27H30ClFN4O3
Molecular Weight:
513.01
AlogP:
3.98
PSA:
65.86
HBD:
0.0
HBA:
#RotB:
5.0
Source:
SCH-900271
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Hydroxycarboxylic acid receptor 2 agonist
SCH-900271
×
Maximum Phase:
2
First Approval:
None
UNII:
G2283XQ6VJ
Molecule Type:
Small molecule
Molecular Formula:
C14H16N2O4
Molecular Weight:
276.29
AlogP:
1.29
PSA:
95.93
HBD:
2.0
HBA:
#RotB:
4.0
Source:
NAVEGLITAZAR
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Peroxisome proliferator-activated receptor alpha agonist
NAVEGLITAZAR
×
Maximum Phase:
2
First Approval:
None
UNII:
Y995M7GM0G
Molecule Type:
Small molecule
Molecular Formula:
C25H26O6
Molecular Weight:
422.48
AlogP:
4.97
PSA:
74.22
HBD:
1.0
HBA:
#RotB:
12.0
Source:
VARLITINIB
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Neoplasms; Pancreatic Neoplasms; Biliary Tract Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Stomach Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
VARLITINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
846Y8197W1
Molecule Type:
Small molecule
Molecular Formula:
C22H19ClN6O2S
Molecular Weight:
466.95
AlogP:
5.25
PSA:
93.55
HBD:
2.0
HBA:
#RotB:
6.0
Source:
HYPOCHLOROUS ACID
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Foot; Infections
Unknown
HYPOCHLOROUS ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
712K4CDC10
Molecule Type:
Small molecule
Molecular Formula:
HClO
Molecular Weight:
52.46
AlogP:
0.13
PSA:
20.23
HBD:
1.0
HBA:
#RotB:
0.0
Source:
METHOXYVERAPAMIL
2
Small molecule
Investigational
Unknown
Unknown
Asthma
Unknown
METHOXYVERAPAMIL
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C26H36N2O3
Molecular Weight:
424.59
AlogP:
5.08
PSA:
54.72
HBD:
0.0
HBA:
#RotB:
12.0
Source:
MIRANSERTIB
2
Small molecule
Investigational
Unknown
Unknown
Endometrial Neoplasms; Lymphoma; Ovarian Neoplasms; Proteus Syndrome
Serine/threonine-protein kinase AKT inhibitor
MIRANSERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
T1DQI1B52Y
Molecule Type:
Small molecule
Molecular Formula:
C27H24N6
Molecular Weight:
432.53
AlogP:
5.07
PSA:
95.64
HBD:
2.0
HBA:
#RotB:
4.0
Source:
GLYCYRRHIZIN
2
Small molecule
Investigational
Unknown
Unknown
Renal Insufficiency, Chronic
Unknown
GLYCYRRHIZIN
×
Maximum Phase:
2
First Approval:
None
UNII:
6FO62043WK
Molecule Type:
Small molecule
Molecular Formula:
C42H62O16
Molecular Weight:
822.94
AlogP:
2.25
PSA:
267.04
HBD:
8.0
HBA:
#RotB:
7.0
Source:
1
2
…
126
127
128
129
130
131
132
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA